Compare Crispr Therapeutics AG (CRSP) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Zoom Video Communications, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.37 (market cap $4.97B), while Zoom Video Communications, Inc. trades at $92.23 (market cap $26.73B). The key difference: Zoom Video Communications, Inc. is far larger — about 5.4× Crispr Therapeutics AG's market cap, and Zoom Video Communications, Inc. is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | ZM | |
|---|---|---|
Market Cap | $4.97B | $26.73B |
Sector | Health | Technology |
52-Week High | $76.78 | $111.88 |
52-Week Low | $44.34 | $69.77 |
Enterprise Value | $3.32B | $19.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Zoom Communications (ZM) trades at $91.88, up 2.36% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows strong profitability with a net income margin of 41.99% and a P/E ratio of 13.53, trading below the analyst consensus price target of $118.79. Recent developments include the acquisition of Common Room and expansion of AI-powered Zoom Virtual Agent capabilities, signaling growth initiatives.
The outlook for ZM is positive, supported by robust cash flow, AI integration, and an undervalued stake in Anthropic ahead of its IPO. Risks include competitive pressure from Microsoft and Google, insider selling, and fluctuating cash flow trends. Wall Street sentiment is mixed, with 39% of analysts rating it a buy, but the stock offers value if execution on AI-driven growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
